Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways
Clinical and Molecular Hepatology 2022 Impact factor 14.0
Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim
Diagnostic Performance of Noninvasive Tests in Patients with MetALD in a Health Check-up Cohort
Journal of Hepatology 2024 Impacf factor: 25.0
Joo Hyun Oh, Sang Bong Ahn, Seon Cho, Eun-Hee Nah, Eileen L. Yoon, Dae Won Jun
Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim
Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?
Journal of Hepatology Impact Factor 25.0 2021
Huiyul Park, Eileen L. Yoon, Seon Cho, Eun-Hee Nah, Dae Won Jun
Necroptosis signaling in liver diseases: An update
Pharmacol Res 2019 Impact factor 9.1
Waqar Khalid Saeed, Dae Won Jun, Kiseok Jang, Dong Hee Koh
Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.
GUT 2021 Impacf factor 23.0
Huiyul Park, Eileen L Yoon, Seon Cho, Dae Won Jun, Eun-Hee Nah
Viewpoint: necroptosis influences the type of liver cancer via changes of hepatic microenvironment
Hepatobiliary Surg Nutr 2019 Impact factor 7.2
Waqar K Saeed, Dae Won Jun
Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
Hepatology 2024 Impact factor 17.3
Chul-Min Lee, Eileen L Yoon, Mimi Kim, Bo-Kyeong Kang, Seon Cho, Eun-Hee Nah, Dae Won Jun
Ticagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease
Nutrients 2024 Impact factor 5.9
Eun Jeoung Lee, Seung Min Lee, Ju Hee Oh, Hye Young Kim, Waqar Khalid Saeed, Hyun Sung Kim, Dae Won Jun
Is lifestyle modification effective for individuals with high fibrosis-4 index without an additional 2nd tier test?
Hepatology 2023 Impact factor 17.3
Huiyul Park, Eileen L Yoon, Mimi Kim, Sun-Hong Kwon, Dae Won Jun, Hye-Lin Kim
